Questions & Answers

The FOxTROT trial supports 6 weeks of neoadjuvant chemotherapy prior to the resection of operable, locally advanced colon cancer, but this issue remains controversial. Meanwhile, the nonrandomized NICHE trials reported high rates of pathologic response to neoadjuvant immunotherapy in patients with dMMR tumors. Presenters will discuss the data for and against the use of neoadjuvant chemotherapy and immunotherapy for locally advanced tumors.